

03C0-4-21-95

#8  
MS  
06/11/96

PATENT  
Atty Dkt: 203442107000  
Client: 1070

I hereby certify that this correspondence is being deposited with the  
United States Postal Service as first class mail in an envelope  
addressed to: Assistant Commissioner for Patents, Washington,  
D.C. 20231. NOVEMBER 16, 1995

11/16/95  
Date

Jean L. Lurie  
Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

VISHVA M. DIXIT et al.

Serial No.: 08/416,379

Group Art Unit: Unknown

Filing Date: April 3, 1995

Examiner: Unassigned

Title: METHODS AND COMPOSITIONS  
FOR REGULATING FAS-  
ASSOCIATED APOPTOSIS

INFORMATION DISCLOSURE  
STATEMENT UNDER 37 CFR § 1.97

Assistant Commissioner  
for Patents  
Washington, D.C. 20231

Dear Sir:

The information listed below, which may be material to  
the examination of the above-identified application, was  
disclosed to the Examiner throughout the application as  
originally filed. Copies of the information and completed  
PTO-1449 forms are submitted herewith. The Examiner is  
respectfully requested to make this information of official  
record in the application. The information includes:

Vaux et al., "An evolutionary perspective on apoptosis" Cell  
(1994) 76:777-779.

PATENT  
USSN 08/416,379  
Atty Dkt 203442107000

Ellis et al., "Mechanisms and functions of cell death" Ann. Rev. Cell Biol. (1991) 7:663-698.

Tomei et al., "Apoptosis: The Molecular Basis of Cell Death" Current Communications in Cell & Molecular Biology 3 (1991) Cold Spring Harbor Press, New York. A title page and table of contents are enclosed herewith.

Tomei et al., "Apoptosis II: The Molecular Basis of Cell Death" Current Communications in Cell & Molecular Biology 8 (1994) Cold Spring Harbor Press, New York. A title page and table of contents are enclosed herewith.

Duvall et al., "Death and the cell" Immunol. Today (1986) 7:115-119.

Cohen, "Apoptosis" Immunol. Today (1993) 14:126-130.

Brunner et al., "Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas" Nature (1995) 373:441-444.

Dhein et al., "Autocrine T-cell suicide mediated by APO-1/(Fas/CD95)" Nature (1995) 373:438-441.

Ju et al., "Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation" Nature (1995) 373:444-448.

Itoh et al., "The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis" Cell (1991) 66:233-243.

PATENT  
USSN 08/416,379  
Atty Dkt 203442107000

Tewari et al., "Fas- and tumor necrosis factor-induced apoptosis is inhibited by the poxvirus *crmA* gene product" J. Biol. Chem. (1995) 270:3255-3260.

Yuan et al., "The *C. elegans* cell death gene *ced-3* encodes a protein similar to mammalian interleukin-1 $\beta$ -converting enzyme" Cell (1993) 75:641-652.

Cerretti et al., "Molecular cloning of the interleukin-1 $\beta$  converting enzyme" Science (1992) 256:97-100.

Thornberry et al., "A novel heterodimeric cysteine protease is required for interleukin-1 $\beta$  processing in monocytes" Nature (1992) 356:768-774.

Miura et al., "Induction of apoptosis in fibroblasts by IL-1 $\beta$ -converting enzyme, a mammalian homolog of the *C. elegans* cell death gene *ced-3*" Cell (1993) 75:653-660.

Baglioni, "Mechanisms of cytotoxicity, cytolysis, and growth stimulation by TNF" Tumor Necrosis Factors. The Molecules and Their Emerging Role in Medicine (1992) B. Beutler, M.D., ed., Raven Press, New York. A title page and table of contents are enclosed herewith.

Yonehara et al.. "A cell-killing monoclonal antibody (Anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor" J. Exp. Med. (1989) 169:1747-1756.

Trauth et al., "Monoclonal antibody-mediated tumor regression by induction of apoptosis" Science (1989) 245:301-305.

PATENT  
USSN 08/416,379  
Atty Dkt 203442107000

Watanabe-Fukunaga et al., "Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis" Nature (1992) 356:314-317.

Tartaglia et al., "Two TNF receptors" Immunol. Today (1992) 13:151-153.

Boldin et al., "Self-association of the 'death domains' of the p55 tumor necrosis factor (TNF) receptor and Fas/APO1 prompts signaling for TNF and Fas/APO1 effects" J. Biol. Chem. (1995) 270:387-391.

Song, "Aggregation of the intracellular domain of the Type I tumor necrosis factor receptor defined by the two-hybrid system" J. Biol. Chem. (1994) 269:22492-22495.

Itoh et al., "A novel protein domain required for apoptosis" J. Biol. Chem. (1993) 268:10932-10937.

Bordignon et al., "Retroviral vector-mediated high-efficiency expression of adenosine deaminase (ADA) in hematopoietic long-term cultures of ADA-deficient marrow cells" Proc. Natl. Acad. Sci. USA (1989) 86:6748-6752.

Culver et al., "Lymphocytes as cellular vehicles for gene therapy in mouse and man" Proc. Natl. Acad. Sci. USA (1991) 88:3155-3159.

Rill et al., "An approach for the analysis of relapse and marrow reconstitution after autologous marrow transplantation using retrovirus-mediated gene transfer" Blood (1992) 79:2694-2700.

PATENT  
USSN 08/416,379  
Atty Dkt 203442107000

Anderson, "Human gene therapy" Science (1992) 256:808-813.

Steplewski et al., "Isolation and characterization of anti-monosialoganglioside monoclonal antibody 19-9 class-switch variants" Proc. Natl. Acad. Sci. USA (1985) 82:8653-8657.

Spira et al., "The identification of monoclonal class switch variants by Sib selection and an ELISA assay" J. Immunol. Meth. (1984) 74:307-315.

Oi et al., "Chimeric antibodies" BioTechniques (1986) 4:214-221.

Herlyn et al., "Anti-idiotypic antibodies bear the internal image of a human tumor antigen" Science (1986) 232:100-102.

Spriggs et al., "Tumor necrosis factor expression in human epithelial tumor cell lines" J. Clin. Invest. (1988) 81:455-460.

Watanabe-Fukunaga et al., "The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen" J. Immun. (1992) 148:1274-1279.

Owen-Schaub et al., "Anti-Fas on nonhematopoietic tumors: Levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness" Cancer Res. (1994) 54:1580-1586.

Oripipari, Jr. et al., "The A20 zinc finger protein protects cells from tumor necrosis factor cytotoxicity" J. Biol. Chem. (1992) 267:12424-12427.

PATENT  
USSN 08/416,379  
Atty Dkt 203442107000

Lum et al., "Coactivation with anti-CD28 monoclonal antibody enhances anti-CD3 monoclonal antibody-induced proliferation and IL-2 synthesis in T cells from autologous bone marrow transplant recipients" Bone Marrow Transplantation (1993) 12:565-571.

Hu et al., "A novel RING finger protein interacts with the cytoplasmic domain of CD40" J. Biol. Chem. (1994) 269:30069-30072.

Higuchi et al., "A general method of *in vitro* preparation and specific mutagenesis of DNA fragments: study of protein and DNA interactions" Nucl. Acids Res. (1988) 16:7351-7367.

Ron et al., "pGSTag - a versatile bacterial expression plasmid for enzymatic labeling of recombinant proteins" BioTechniques (1992) 13:866-869.

Studier, "Use of bacteriophage T7 lysozyme to improve an inducible T7 expression system" J. Mol. Biol. (1991) 219:37-44.

Harper et al., "The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases" Cell (1993) 75:805-816.

O'Rourke et al., "Thrombospondin 1 and Thrombospondin 2 are expressed as both homo- and heterotrimers" J. Biol. Chem. (1992) 267:24921-24924.

Peters et al., "Ankyrins: Structure and function in normal cells and hereditary spherocytes" Seminars in Hematol. (1993) 30:85-118.

PATENT  
USSN 08/416,379  
Atty Dkt 203442107000

Clement et al., "Fas and tumor necrosis factor receptor-mediated cell death: Similarities and distinctions" J. Exp. Med. (1994) 180:557-567.

The references above are summarized throughout the application as originally filed. The summaries contain what the undersigned believes to be the salient aspects of the cited references. They are not intended to be a comprehensive statement of the relevance of the references to the subject invention.

This Information Disclosure Statement is submitted before receipt of the first Office Action on Merits. Therefore, the applicants believe that no fee is due. However, the Commissioner is hereby authorized to charge any fees which may be required by this paper to Deposit Account Number 03-1952.

Applicants would appreciate the Examiner's initialling and returning the Form PTO-1449, indicating that the references have indeed been considered and made of record herein.

This Information Disclosure Statement under 37 CFR § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or

PATENT  
USSN 08/416,379  
Atty Dkt 203442107000

(iv) the above information constitutes prior art to the subject invention.

Respectfully submitted,

By *Antoinette F. Konski*  
Antoinette F. Konski  
Registration No. 34,202  
Date: Nov. 15, 1995

MORRISON & FOERSTER  
755 Page Mill Road  
Palo Alto, CA 94304-1018  
(415) 813-5600  
Fax: (415) 494-0792